SCHEMBL20162151

SCHEMBL20162151

COC(=O)/C=C/c1ccc2c(c1)CCN(C(=O)O)C2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.48
ALDH1A1 P00352 3/20 0.48
MAPT P10636 3/20 0.48
HPGD P15428 2/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
TTR P02766 1/20 0.48
APP P05067 1/20 0.48
BCHE P06276 5/20 0.47
MAOA P21397 5/20 0.47
ACHE P22303 5/20 0.47
MAOB P27338 5/20 0.47
HDAC1 Q13547 4/20 0.46
PTPN1 P18031 1/20 0.46
EPHX2 P34913 1/20 0.45
ATM Q13315 1/20 0.45
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
TYR P14679 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27766220 0.95 KDM4E (0.48) KDM4EALDH1A1MAPTHPGDMEN1
SCHEMBL27766256 0.90 HDAC1 (0.53) KDM4EALDH1A1MAPTTTRAPP
SCHEMBL20995789 0.87 TTR (0.51) KDM4EALDH1A1MAPTHPGDMEN1
SCHEMBL20995788 0.87 TTR (0.51) KDM4EALDH1A1MAPTHPGDMEN1
SCHEMBL20367229 0.85 HDAC1 (0.64) KDM4EALDH1A1MAPTHPGDMEN1
SCHEMBL7974049 0.82 TTR (0.51) KDM4EALDH1A1MAPTHPGDMEN1
SCHEMBL7974045 0.82 TTR (0.51) KDM4EALDH1A1MAPTHPGDMEN1
SCHEMBL8204673 0.80 MAPT (0.47) KDM4EALDH1A1MAPTHPGDMEN1
SCHEMBL8204675 0.80 MAPT (0.47) KDM4EALDH1A1MAPTHPGDMEN1
SCHEMBL3185199 0.80 HDAC1 (0.64) KDM4EALDH1A1MAPTHPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10294237-B2 Bicyclic heterocyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2019-05-21 US disclosed
US-20180194773-A1 BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2018-07-12 US disclosed
EP-3323809-A1 BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE Sumitomo Dainippon Pharma Co., Ltd. (JP) 2018-05-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10294237-B2 Bicyclic heterocyclic amide derivative NR0B1, NR2E1, NR0B2 KDM4E 2080/4885ALDH1A1 625/4885MAPT 4815/4885
US-20180194773-A1 BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE NR0B1, NR2E1, NR0B2 KDM4E 2080/4885ALDH1A1 625/4885MAPT 4815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.